NeuroSense Therapeutics LtdNRSN
Price$3.07

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 31 Dec 2025
Net Income -$11.1MTTM through 31 Dec 2025
Free Cash Flow -$7.7MTTM through 31 Dec 2025

Margins

Current

Returns

N/A (negative equity)ROE

Balance Sheet Health

Debt / EquityN/A (negative equity)
Current Ratio0.31x
Net Debt-$166Knet cash position
Cash & Equivalents$166K

Quality Metrics

Altman Z-Score-99.53
Piotroski F-Score2 / 9

Multi-Year Trend

Diluted EPS-$0.44TTM
'22'23'24'25
FY2025: $-0.44

Dividend

No dividend

Capital Allocation

R&D Spend$6.2M
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.